Myocardial ischemia occurs when blood flow to your heart is reduced, preventing it from receiving enough oxygen. The reduced blood flow is usually the result of a partial or complete blockage of your heart's arteries (coronary arteries).
Myocardial ischemia, also called cardiac ischemia, can damage your heart muscle, reducing its ability to pump efficiently. A sudden, severe blockage of a coronary artery can lead to a heart attack. Myocardial ischemia might also cause serious abnormal heart rhythms.
Key Players of Ischemia Reperfusion Injury Market: Pipeline Review, H1 are Akashi Therapeutics Inc, Angion Biomedica Corp, Boehringer Ingelheim GmbH, Bolder Biotechnology Inc, Catalyst Biosciences Inc, Cellmid Ltd, CFM Pharma Holding BV
DECEMBER 13, 2017 BY ANDRZEJ
Myocardial Ischemia Drugs Market – Global Market Research Data Covering Baxalta Incorporated, Bayer AG, Cellmid Limited
What value would a phase 1 Myocardial ischemia program with a reputable partner add to market capitalisation of Cellmid? = upwards of $20m?
2018 - The Year of the BioTechs, page-45
-
- There are more pages in this discussion • 631 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
